Intercept’s NASH hopeful spurned by FDA, raising questions for other companies in the race
Intercept Pharmaceuticals, long the frontrunner in non-alcoholic steatohepatitis (NASH), has suffered several delays on its FDA application for obeticholic acid (OCA). Now, the company has received an outright rejection from the agency in a decision that could affect the prospects for other companies in the field. Following delays that centered on advisory committee scheduling and… Read More »
